Bispecific antibodies, nanoparticles and cells: Bringing the right cells to get the job done

Expert Opinion on Biological Therapy

Volumn 15, Issue 9, 2015, Pages 1251-1255

  Tang, Junnan ^a,b   Shen, Deliang ^b   Zhang, Jinying ^b   Ligler, Frances S ^a   Cheng, Ke ^a,c  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Bispecific antibody; cell therapy; cytotoxic T cells; magnetic nanoparticles; regenerative medicine

Indexed keywords

BISPECIFIC ANTIBODY; IRON NANOPARTICLE; MAGNETIC BISPECIFIC CELL ENGAGER; UNCLASSIFIED DRUG; CD45 ANTIGEN; MYOSIN LIGHT CHAIN; NANOPARTICLE;

CELL THERAPY; HEART INFARCTION; HEMATOPOIETIC STEM CELL; MAGNETIC FIELD; NANOTECHNOLOGY; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MAGNETISM; METABOLISM; MOUSE; MYOCARDIAL INFARCTION; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

RODENTIA;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD45; LYMPHOCYTE ACTIVATION; MAGNETICS; MICE; MYOCARDIAL INFARCTION; MYOSIN LIGHT CHAINS; NANOPARTICLES; STEM CELL TRANSPLANTATION; STEM CELLS; T-LYMPHOCYTES;

EID: 84938848237     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1049944     Document Type: Review

References (15)

1. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 2010; 12: 340-9
2. Lum LG, Davol PA, Lee RJ. The new face of bispecific antibodies: targeting cancer and much more. Exp Hematol 2006; 34: 1-6
3. Cheng K, Shen D, Hensley MT, et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat Commun 2014; published online 10 September 2014; 10.1038/ncomms5880
4. Choi BD, Cai M, Bigner DD, et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011; 11: 843-53
5. De Gast GC, Van Houten AA, Haagen IA, et al. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995; 4: 433-7
6. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4
7. Davol PA, Smith JA, Kouttab N, et al. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer 2004; 3: 112-21
8. Reusch U, Sundaram M, Davol PA, et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 2006; 12: 183-90
9. Lee RJ, Fang Q, Davol PA, et al. Antibody targeting of stem cells to infarcted myocardium. Stem Cells 2007; 25: 712-17
10. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 14-18
11. + cell transplantation combined with off-pump coronary artery bypass grafting. Heart Surg Forum 2004; 7: 285-7
12. + hematopoietic stem cells with anti-CD45 × anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction. J Appl Physiol (1985). 2008; 104: 1793-800
13. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021
14. Cheng K, Li TS, Malliaras K, et al. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010; 106: 1570-81
15. Cheng K, Malliaras K, Li TS, et al. Magnetic enhancement of cell retention, engraftment, and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant 2012; 21: 1121-35